Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + Temsirolimus

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ganglioneuroblastoma

Conditions

Ganglioneuroblastoma, Recurrent Neuroblastoma

Trial Timeline

Feb 12, 2013 → Sep 30, 2022

NCT ID

NCT01767194

About Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + Temsirolimus

Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + Temsirolimus is a phase 2 stage product being developed by United Therapeutics for Ganglioneuroblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01767194. Target conditions include Ganglioneuroblastoma, Recurrent Neuroblastoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01767194	Phase 2	Completed	Feb 12, 2013	Sep 30, 2022	Ganglioneuroblastoma